Marius Hoerner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marius Hoerner has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Daniel E. Johnson
Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA
5 shared publications - Jacqueline P. Nguyen
Department of Otolaryngology–Head and Neck Surgery, University of California, San Francisco, California
5 shared publications - Jennifer R. Grandis
Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA
5 shared publications - Kelly Blum
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
5 shared publications - Liam C. Woerner
Department of Otolaryngology–Head and Neck Surgery, University of California, San Francisco, California
5 shared publications - Mi-Ok Kim
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
5 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Springer Nature in Oral and Maxillofacial Surgery
- Vol. 30 (1) , 149
Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma
Background: PD-L1 expression is an established predictive biomarker for immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), including oral squamous cell carcinoma (OSCC). However, the spatial heterogeneity of PD-L1 and additional biomarkers such as c-MET between primary tumors and lymph node metastases remains insufficiently characterized. Given the potential for compartment-specific biomarker differences between primary tumors and metastatic lesions, we investigated PD-L1 and c-MET expression patterns in matched primary tumors and lymph node metastases of OSCC patients. Methods: In this retrospective cohort study, PD-L1 expression (Tumor Proportion Score [TPS], Combined Positive Score [CPS]) and c-MET expression (H-score, percentage-based scoring) were analyzed by immunohistochemistry in primary tumors from 59 OSCC patients. Matched primary tumor–lymph node metastasis pairs were available for 24 patients and served as the basis for the paired spatial heterogeneity analyses. Biomarker concordance between primary tumors and metastases as well as associations with clinicopathologic parameters were evaluated. Results: Both PD-L1 and c-MET were frequently expressed in primary tumors but showed significantly lower expression levels in matched lymph node metastases. Higher PD-L1 expression in primary tumors was associated with nodal metastasis in exploratory analyses, whereas c-MET expression showed no significant association with nodal status. No significant correlation between PD-L1 and c-MET expression was observed. Furthermore, discordance of PD-L1 CPS status between primary tumors and lymph node metastases resulted in different biomarker classifications in a substantial subset of matched cases. In exploratory analyses, biomarker expression and primary tumor–lymph node discordance were not significantly associated with recurrence, although the limited number of events precludes definitive conclusions. Conclusions: Our findings demonstrate pronounced spatial heterogeneity of PD-L1 and c-MET expression in OSCC and reveal compartment-specific biomarker expression patterns between primary tumors and lymph node metastases. The observed discordance between tumor compartments warrants further investigation in larger prospective studies to determine its biological and potential clinical relevance for biomarker assessment in OSCC.
- 16 September 2026
- Published by Springer Nature in Oral and Maxillofacial Surgery
- Vol. 30 (1) , 149
Open AccessExploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma
Background: PD-L1 expression is an established predictive biomarker for immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), including oral squamous cell carcinoma (OSCC). However, the spatial heterogeneity of PD-L1 and additional biomarkers such as c-MET between primary tumors and lymph node metastases remains insufficiently characterized. Given the potential for compartment-specific biomarker differences between primary tumors and metastatic lesions, we investigated PD-L1 and c-MET expression patterns in matched primary tumors and lymph node metastases of OSCC patients. Methods: In this retrospective cohort study, PD-L1 expression (Tumor Proportion Score [TPS], Combined Positive Score [CPS]) and c-MET expression (H-score, percentage-based scoring) were analyzed by immunohistochemistry in primary tumors from 59 OSCC patients. Matched primary tumor–lymph node metastasis pairs were available for 24 patients and served as the basis for the paired spatial heterogeneity analyses. Biomarker concordance between primary tumors and metastases as well as associations with clinicopathologic parameters were evaluated. Results: Both PD-L1 and c-MET were frequently expressed in primary tumors but showed significantly lower expression levels in matched lymph node metastases. Higher PD-L1 expression in primary tumors was associated with nodal metastasis in exploratory analyses, whereas c-MET expression showed no significant association with nodal status. No significant correlation between PD-L1 and c-MET expression was observed. Furthermore, discordance of PD-L1 CPS status between primary tumors and lymph node metastases resulted in different biomarker classifications in a substantial subset of matched cases. In exploratory analyses, biomarker expression and primary tumor–lymph node discordance were not significantly associated with recurrence, although the limited number of events precludes definitive conclusions. Conclusions: Our findings demonstrate pronounced spatial heterogeneity of PD-L1 and c-MET expression in OSCC and reveal compartment-specific biomarker expression patterns between primary tumors and lymph node metastases. The observed discordance between tumor compartments warrants further investigation in larger prospective studies to determine its biological and potential clinical relevance for biomarker assessment in OSCC.
- Open Access
- 15 September 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (10) , 287
HGF/c-MET signaling induces glutamine metabolism in MET-amplified head and neck squamous cell carcinoma via MAPK/ERK-dependent induction of GLS-1
Head and neck squamous cell carcinoma (HNSCC) is a common malignancy characterized by poor survival due to recurrence, metastasis and therapy resistance. In addition to genetic alterations, metabolic reprogramming is a hallmark of HNSCC and contributes to tumor progression and treatment failure. The hepatocyte growth factor (HGF)/c-MET signaling pathway is frequently activated in head and neck squamous cell carcinoma (HNSCC), where it promotes tumor cell proliferation, invasion, and increased glucose metabolism. However, its contribution to the regulation of glutamine metabolism in HNSCC remains largely unexplored. Basal GLS-1 expression was compared between primary human oral keratinocytes (HOK) and HNSCC cell lines with distinct MET status (Detroit 562, FaDu, and SCC-154). Subsequently, HNSCC cell lines were stimulated with HGF, and GLS-1 expression was assessed by quantitative PCR and Western blotting. Functional effects were evaluated using wound-healing assays, enzymatic quantification of extracellular glutamine and glutamate, and Seahorse-based mitochondrial respiration analysis. GLS-1 was silenced using siRNA to determine its functional relevance. In addition, transcriptomic data from the TCGA-HNSC cohort were analyzed to evaluate the clinical association between MET signaling, MAPK/ERK pathway activity, and GLS1 expression. HGF stimulation selectively induced GLS-1 expression in MET-amplified Detroit 562 cells at both mRNA and protein levels, whereas MET wild-type cells remained largely unaffected. Mechanistically, HGF triggered robust ERK1/2 activation, and pharmacological inhibition of c-MET or ERK signaling abrogated GLS-1 induction. Functionally, HGF increased glutamine consumption, glutamate production, and mitochondrial respiratory capacity in a GLS-1–dependent manner, while GLS-1 silencing significantly impaired HGF-induced cell migration and mitochondrial respiration. Importantly, analysis of TCGA-HNSC tumors revealed significant correlations between MET expression, MAPK/ERK pathway activity, and GLS1 expression, supporting the clinical relevance of the identified signaling axis. Together, these findings identify GLS-1 as a downstream effector of HGF/c-MET–MAPK/ERK signaling in MET-amplified HNSCC and link oncogenic signaling to glutamine metabolism and mitochondrial function. The observed associations in TCGA patient tumors further support the clinical relevance of this pathway and suggest that targeting glutaminase or ERK signaling may represent a promising therapeutic strategy in c-MET–driven HNSCC. Graphic abstract The schematic summarizes the proposed mechanism: HGF binding to the c-MET receptor activates the MAPK/ERK signaling pathway, resulting in transcriptional upregulation of GLS-1. Increased GLS-1 expression enhances glutamine metabolism and mitochondrial oxidative phosphorylation, thereby promoting metabolic reprogramming and increased cell motility in MET-amplified HNSCC cells. Pharmacologic inhibition of c-MET or ERK1/2, as well as GLS-1 silencing, disrupts this signaling axis, attenuating both metabolic activity and HGF-driven migration. Collectively, these findings identify GLS-1 as a critical downstream effector of HGF/c-MET signaling that links oncogenic signaling to metabolic adaptation and tumor progression in HNSCC. Created in BioRender. Schlegel, N. (2026) https://BioRender.com/l8a7a1t
- 15 September 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (10) , 287
Open AccessHGF/c-MET signaling induces glutamine metabolism in MET-amplified head and neck squamous cell carcinoma via MAPK/ERK-dependent induction of GLS-1
Head and neck squamous cell carcinoma (HNSCC) is a common malignancy characterized by poor survival due to recurrence, metastasis and therapy resistance. In addition to genetic alterations, metabolic reprogramming is a hallmark of HNSCC and contributes to tumor progression and treatment failure. The hepatocyte growth factor (HGF)/c-MET signaling pathway is frequently activated in head and neck squamous cell carcinoma (HNSCC), where it promotes tumor cell proliferation, invasion, and increased glucose metabolism. However, its contribution to the regulation of glutamine metabolism in HNSCC remains largely unexplored. Basal GLS-1 expression was compared between primary human oral keratinocytes (HOK) and HNSCC cell lines with distinct MET status (Detroit 562, FaDu, and SCC-154). Subsequently, HNSCC cell lines were stimulated with HGF, and GLS-1 expression was assessed by quantitative PCR and Western blotting. Functional effects were evaluated using wound-healing assays, enzymatic quantification of extracellular glutamine and glutamate, and Seahorse-based mitochondrial respiration analysis. GLS-1 was silenced using siRNA to determine its functional relevance. In addition, transcriptomic data from the TCGA-HNSC cohort were analyzed to evaluate the clinical association between MET signaling, MAPK/ERK pathway activity, and GLS1 expression. HGF stimulation selectively induced GLS-1 expression in MET-amplified Detroit 562 cells at both mRNA and protein levels, whereas MET wild-type cells remained largely unaffected. Mechanistically, HGF triggered robust ERK1/2 activation, and pharmacological inhibition of c-MET or ERK signaling abrogated GLS-1 induction. Functionally, HGF increased glutamine consumption, glutamate production, and mitochondrial respiratory capacity in a GLS-1–dependent manner, while GLS-1 silencing significantly impaired HGF-induced cell migration and mitochondrial respiration. Importantly, analysis of TCGA-HNSC tumors revealed significant correlations between MET expression, MAPK/ERK pathway activity, and GLS1 expression, supporting the clinical relevance of the identified signaling axis. Together, these findings identify GLS-1 as a downstream effector of HGF/c-MET–MAPK/ERK signaling in MET-amplified HNSCC and link oncogenic signaling to glutamine metabolism and mitochondrial function. The observed associations in TCGA patient tumors further support the clinical relevance of this pathway and suggest that targeting glutaminase or ERK signaling may represent a promising therapeutic strategy in c-MET–driven HNSCC. Graphic abstract The schematic summarizes the proposed mechanism: HGF binding to the c-MET receptor activates the MAPK/ERK signaling pathway, resulting in transcriptional upregulation of GLS-1. Increased GLS-1 expression enhances glutamine metabolism and mitochondrial oxidative phosphorylation, thereby promoting metabolic reprogramming and increased cell motility in MET-amplified HNSCC cells. Pharmacologic inhibition of c-MET or ERK1/2, as well as GLS-1 silencing, disrupts this signaling axis, attenuating both metabolic activity and HGF-driven migration. Collectively, these findings identify GLS-1 as a critical downstream effector of HGF/c-MET signaling that links oncogenic signaling to metabolic adaptation and tumor progression in HNSCC. Created in BioRender. Schlegel, N. (2026) https://BioRender.com/l8a7a1t
- Open Access
Quantifying the Oral Cancer Public Awareness Deficit in Germany (2015–2023)
Objective: To quantify the gap between oral cancer disease burden and public awareness in Germany, and to characterize research dissemination patterns across social media platforms. Methods: We conducted a multi-dimensional analysis integrating: (1) Robert Koch Institut cancer registry data for oral and maxillofacial malignancies (ICD-10: C00–C06) from 2015 to 2023; (2) Google Trends search interest for cancer-related German terms; (3) Altmetric data for 2581 PubMed-indexed oral cancer publications; and (4) sentiment analysis of 10,308 social media posts. Age-standardized incidence rates were calculated using the European Standard Population. Results: Over the study period, 65,757 oral cavity cancer cases were registered. Google Trends analysis revealed a 64% attention deficit for “Mundkrebs” (oral cancer; mean: 17) compared to “Brustkrebs” (breast cancer; mean: 47). Case numbers declined from 7577 (2019) to 6870 (2023; −9.3%), while age-standardized rates decreased by 15.5% (11.6 to 9.8 per 100,000), with males disproportionately affected (−17.7%). Research dissemination was dominated by X/Twitter (86.2%), with minimal policy document (0.3%) or clinical guideline (0.3%) citations. Sentiment analysis revealed 77% positive public reception. Regional analysis identified an East–West divide, with Eastern German states showing 22% higher search interest. Conclusions: A substantial public awareness deficit exists for oral cancer in Germany, paradoxically widening during a period of declining diagnoses potentially associated with COVID-19-related diagnostic delays. The positive public sentiment toward oral cancer research suggests a favorable environment for targeted awareness campaigns, particularly in Western German states where search interest is lowest. These findings have practical implications for designing regionally tailored awareness campaigns prioritizing anatomically specific terminology. Future research should evaluate the effectiveness of such targeted interventions and assess whether post-pandemic diagnoses present at more advanced stages.
Open AccessQuantifying the Oral Cancer Public Awareness Deficit in Germany (2015–2023)
Objective: To quantify the gap between oral cancer disease burden and public awareness in Germany, and to characterize research dissemination patterns across social media platforms. Methods: We conducted a multi-dimensional analysis integrating: (1) Robert Koch Institut cancer registry data for oral and maxillofacial malignancies (ICD-10: C00–C06) from 2015 to 2023; (2) Google Trends search interest for cancer-related German terms; (3) Altmetric data for 2581 PubMed-indexed oral cancer publications; and (4) sentiment analysis of 10,308 social media posts. Age-standardized incidence rates were calculated using the European Standard Population. Results: Over the study period, 65,757 oral cavity cancer cases were registered. Google Trends analysis revealed a 64% attention deficit for “Mundkrebs” (oral cancer; mean: 17) compared to “Brustkrebs” (breast cancer; mean: 47). Case numbers declined from 7577 (2019) to 6870 (2023; −9.3%), while age-standardized rates decreased by 15.5% (11.6 to 9.8 per 100,000), with males disproportionately affected (−17.7%). Research dissemination was dominated by X/Twitter (86.2%), with minimal policy document (0.3%) or clinical guideline (0.3%) citations. Sentiment analysis revealed 77% positive public reception. Regional analysis identified an East–West divide, with Eastern German states showing 22% higher search interest. Conclusions: A substantial public awareness deficit exists for oral cancer in Germany, paradoxically widening during a period of declining diagnoses potentially associated with COVID-19-related diagnostic delays. The positive public sentiment toward oral cancer research suggests a favorable environment for targeted awareness campaigns, particularly in Western German states where search interest is lowest. These findings have practical implications for designing regionally tailored awareness campaigns prioritizing anatomically specific terminology. Future research should evaluate the effectiveness of such targeted interventions and assess whether post-pandemic diagnoses present at more advanced stages.
- Open Access
- 19 February 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (3) , 156
Loss of junctional plakoglobin (JUP) activates PI3K/AKT signaling in head and neck squamous cell carcinoma
Head and neck squamous cell carcinomas (HNSCC) are characterized by poor prognosis, primarily due to early metastatic spread. The junctional plaque protein plakoglobin (JUP), a key desmosomal component, contributes not only to cell–cell adhesion but also to intracellular signaling processes that regulate proliferation, migration, and metastasis. Although JUP has been implicated in tumor progression in other cancer types, its role in HNSCC remains largely undefined. In this study, clinical data from The Cancer Genome Atlas (TCGA) were analyzed to determine the prognostic relevance of JUP expression in HNSCC. Functional studies were performed in HPV-negative (FaDu) and HPV-positive (UPCI-SCC-154) cells following siRNA-mediated JUP knockdown, assessing proliferation, wound healing, and signaling activity. Pharmacological inhibition experiments were conducted to evaluate pathway specificity. Low JUP expression was significantly associated with advanced metastatic stage and reduced overall survival in HNSCC patients. In vitro, JUP-deficient cells exhibited accelerated wound closure and increased proliferation. Mechanistically, loss of JUP led to activation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, and the enhanced motility phenotype could be reversed by pharmacological PI3K inhibition. Taken together, these findings identify plakoglobin as a negative regulator of PI3K signaling in HNSCC. Loss of JUP promotes tumor cell motility and proliferation, underscoring its potential value as a prognostic biomarker and therapeutic target in head and neck cancer.
- 19 February 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (3) , 156
Open AccessLoss of junctional plakoglobin (JUP) activates PI3K/AKT signaling in head and neck squamous cell carcinoma
Head and neck squamous cell carcinomas (HNSCC) are characterized by poor prognosis, primarily due to early metastatic spread. The junctional plaque protein plakoglobin (JUP), a key desmosomal component, contributes not only to cell–cell adhesion but also to intracellular signaling processes that regulate proliferation, migration, and metastasis. Although JUP has been implicated in tumor progression in other cancer types, its role in HNSCC remains largely undefined. In this study, clinical data from The Cancer Genome Atlas (TCGA) were analyzed to determine the prognostic relevance of JUP expression in HNSCC. Functional studies were performed in HPV-negative (FaDu) and HPV-positive (UPCI-SCC-154) cells following siRNA-mediated JUP knockdown, assessing proliferation, wound healing, and signaling activity. Pharmacological inhibition experiments were conducted to evaluate pathway specificity. Low JUP expression was significantly associated with advanced metastatic stage and reduced overall survival in HNSCC patients. In vitro, JUP-deficient cells exhibited accelerated wound closure and increased proliferation. Mechanistically, loss of JUP led to activation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, and the enhanced motility phenotype could be reversed by pharmacological PI3K inhibition. Taken together, these findings identify plakoglobin as a negative regulator of PI3K signaling in HNSCC. Loss of JUP promotes tumor cell motility and proliferation, underscoring its potential value as a prognostic biomarker and therapeutic target in head and neck cancer.
- Open Access
- 13 August 2025
- Published by Elsevier in Mucosal Immunology
- Vol. 18 (6) , 1257-1270
Junctional epithelial Plakoglobin facilitates intestinal inflammation by p38MAPK-dependent activation of the inflammasome
- 13 August 2025
- Published by Elsevier in Mucosal Immunology
- Vol. 18 (6) , 1257-1270
Open AccessJunctional epithelial Plakoglobin facilitates intestinal inflammation by p38MAPK-dependent activation of the inflammasome
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 2 shows Elevated COX2 protein expression in PTEN-deficient HNSCC cells. COX2 protein expression in PTEN knockout (PTEN KO) in Cal27 human and MOC22 murine cells was increased compared to parental cells.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 2 shows Elevated COX2 protein expression in PTEN-deficient HNSCC cells. COX2 protein expression in PTEN knockout (PTEN KO) in Cal27 human and MOC22 murine cells was increased compared to parental cells.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 1 shows that loss of PTEN increases tumor growth. Tumor cells derived from MOC1 cells with PTEN loss or PIK3CA amplification (WT) or mutation (H1047R, E545K) were implanted subcutaneously in immunocompetent mice and tumor volumes were monitored for 19 days. Tumor volumes for MOC1 cells engineered for PIK3CA mutations H1047R (p=0.032) or E545K (p=0.0023) or PTEN KO (p=0.0079) were increased compared with tumors derived from parental control cells. The mean measurements and SD of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 1 shows that loss of PTEN increases tumor growth. Tumor cells derived from MOC1 cells with PTEN loss or PIK3CA amplification (WT) or mutation (H1047R, E545K) were implanted subcutaneously in immunocompetent mice and tumor volumes were monitored for 19 days. Tumor volumes for MOC1 cells engineered for PIK3CA mutations H1047R (p=0.032) or E545K (p=0.0023) or PTEN KO (p=0.0079) were increased compared with tumors derived from parental control cells. The mean measurements and SD of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 3 shows that TPST-1495 enhances anti-PD1 anti-tumor activity. MOC1 cells engineered to express E545K PIK3CA mutation (2x106 cell/mouse) were implanted subcutaneously into flanks of immunocompetent C57BL/6 mice. Once tumors were palpable (about 100 mm3; approximately 10 days), mice were treated with vehicle (methylcellulose bi-daily and/or IgG), TPST-1495 (150 mg/kg, bi-daily), anti-PD1 (0.2 mg per mouse on days 1, 4, and 7 after palpable tumors were established), or the combination of TPST-1495 and anti-PD1 (n=5 per group). Concomitant administration of TPST-1495 and anti-PD1 showed an additive effect on tumor growth inhibition compared to anti-PD1 (p=0.001) alone. The mean measurements and SEM of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 3 shows that TPST-1495 enhances anti-PD1 anti-tumor activity. MOC1 cells engineered to express E545K PIK3CA mutation (2x106 cell/mouse) were implanted subcutaneously into flanks of immunocompetent C57BL/6 mice. Once tumors were palpable (about 100 mm3; approximately 10 days), mice were treated with vehicle (methylcellulose bi-daily and/or IgG), TPST-1495 (150 mg/kg, bi-daily), anti-PD1 (0.2 mg per mouse on days 1, 4, and 7 after palpable tumors were established), or the combination of TPST-1495 and anti-PD1 (n=5 per group). Concomitant administration of TPST-1495 and anti-PD1 showed an additive effect on tumor growth inhibition compared to anti-PD1 (p=0.001) alone. The mean measurements and SEM of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 20 February 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 931-941
Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- 20 February 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 931-941
Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.